08/03/2026
🤔 When does healthy skepticism become a barrier to innovation?
For this edition of Publication Discussions, we explore a study examining how Canadian healthcare providers view psychedelic-assisted therapies across clinical settings, including oncology and palliative care.
Rather than finding providers who were either “for” or “against” psychedelic-assisted therapies, the researchers found a much more nuanced picture. Most participants expressed cautious optimism—recognizing the therapeutic potential while also raising important questions about safety, evidence, regulation, training, and implementation.
The study also highlights that integrating a new therapy into healthcare depends on much more than clinical evidence alone. Healthcare providers identified practical barriers such as limited clinical guidelines, funding, infrastructure, education, trained providers and regulatory uncertainty, all of which influence whether innovative treatments can become part of routine care.
For CAN-PACT, these findings reinforce that advancing psychedelic-assisted cancer care is about more than generating evidence. It also requires supporting healthcare providers and policymakers with the education, clinical guidance, and systems needed to deliver these therapies safely, ethically, and responsibly.
💬 Final slide question: When does healthy skepticism become a barrier to innovation?
📚 Source: Schuman HDM, Mina R, Barkova S, Nguyen T, Deleemans JM, Carlson LE. Healthcare Providers’ Perspectives on Psychedelic-Assisted Therapies Across Clinical Contexts: “I Can Offer Medical Assistance in Dying, but I Can’t Prescribe Psychedelics”. Global Advances in Integrative Medicine and Health. 2026;15. https://doi.org/10.1177/27536130261459354